Cerevel Therapeutics Holdings, Inc.
Cerevel Therapeutics Holdings, Inc. (CERE) Revenue
Annual & quarterly revenue history · segment & region breakdown
CERE · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsCerevel Therapeutics Holdings, Inc. trailing twelve-month (TTM) revenue is $0.01B, an increase of 0.00% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2012 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-12-31 | $0.00B | +$0.00B | — |
| 2022-12-31 | $0.00B | +$0.00B | — |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | +$0.00B | — |
| 2018-12-31 | $0.00B | -$0.00B | -100.00% |
| 2015-08-31 | $0.00B | +$0.00B | +13.14% |
| 2014-08-31 | $0.00B | -$0.00B | -54.15% |
| 2013-08-31 | $0.01B | -$0.00B | -2.38% |
| 2012-08-31 | $0.01B | — | — |
Compare revenue vs peers
BiotechnologyCompare CERE revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Cerevel Therapeutics Holdings, Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Cerevel Therapeutics Holdings, Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Cerevel Therapeutics Holdings, Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CERE revenue · 4 questionsCERE's trailing twelve-month (TTM) revenue is $0.01B. That is an increase of 0.00% year-over-year from $0.00B in FY2023.
▸ Source: FMP · Cerevel Therapeutics Holdings, Inc. SEC filings · GAAP · Cerevel Therapeutics Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026